27 results about "Protein C" patented technology

A spore of a bacillus subtilis B.subtilis WB600 strain is used as an antigen delivery carrier, spore coat protein C (CotC) is used as anchoring protein, a key protein ATPase gene and a CotC gene of micropterus salmoides iridovirus are fused through a gene fusion technology, a recombinant spore surface display system is constructed, the ATPase antigen is stably displayed on the spore surface, and an oral vaccine is prepared. After being orally applied to fishes, the vaccine can tolerate the gastrointestinal tract environment and is accurately delivered to intestinal related lymphatic tissues to stimulate fish immunity, and finally prevention and control of the iridovirus of the micropterus salmoides are achieved.

The invention provides a porcine deltacoronavirus S1 protein nanoparticle vaccine CTDnps and application thereof, and belongs to the technical field of vaccine preparation. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine capable of being self-assembled, provided by the invention, comprises ferritin and a PDCoV S1 protein C-terminal structural domain, the amino acid sequence of the ferritin is as shown in SEQ ID NO.1, and the amino acid sequence of the PDCoV S1 protein C-terminal structural domain is as shown in SEQ ID NO.2. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine capable of being self-assembled comprises the ferritin and the PDCoV S1 protein C-terminal structural domain. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine (S1CTD-Fer) constructed by the invention can be self-assembled to form ferritin-like cage-shaped nanoparticles, and the hydrodynamic diameter of the cage-shaped nanoparticles is obviously greater than that of natural ferritin nanoparticles. Compared with the S1CTD, the S1CTD-Fel based on the ferritin carrier can obviously enhance the immunogenicity of the S1CTD, can obviously enhance the uptake efficiency of antigen presenting cells, and is high in safety.

The present application provides a vaccine comprising: 1) a peptide oligomer consisting of 2-8 copies of a bacteriophage T4 fibrin C-terminal polypeptide and one or more antigen proteins; or 2) a coding nucleic acid of item 1) wherein 2-8 copies of the bacteriophage T4 fibrin C-terminal polypeptides in the peptide oligomer are directly linked in series through chemical bonds or each of the bacteriophage T4 fibrin C-terminal polypeptides is linked to each other through a peptide linker, and the peptide oligomer and the antigen protein are directly connected through a chemical bond or connected through a peptide linker. In the bi-T4-virus antigen vaccine platform provided by the invention, the antigen can be subjected to multi-component change, that is, the antigen can form a trimer, so that the use flexibility of the vaccine platform is enhanced, the application range of the vaccine platform is widened, and the bi-T4 structure can enhance the formation of trimer protein and enhance the immune aging.

The invention discloses a self-assembled PROTAC nano material based on natural product mitochondria targeting, which is a nano particle prepared from mitochondria targeting molecules, a photosensitizer and PROTAC as raw materials through a nano precipitation method. The mitochondrial targeting molecule is berberine, the photosensitizer is hypericin, and the PROTAC is dBET57; the ratio of the amount of substance of the dBET57 to the amount of substance of the berberine is (1-10): (1-10), and the ratio of the amount of substance of the dBET57 to the amount of substance of the hypericin is (1-10): (1-10). The nano material can be used for blocking multiple energy metabolism pathways of tumor cells, including glycolysis and oxidative phosphorylation, meanwhile, mitochondria is damaged, ferroptosis is induced, and the anti-tumor capacity of pharmacodynamic molecules is improved; bRD4 in tumor cells and downstream carcinogenic protein c-Myc of the BRD4 can be efficiently degraded. The invention also discloses an application of the nano material in preparation of antitumor drugs.

To provide a method for screening an olfactory receptor protein or its combination useful in cancer examination.SOLUTION: A method for screening an olfactory receptor protein or a combination thereof, comprising testing the reactivity of a test olfactory receptor protein to cancer, and selecting at least one selected from the group consisting of (1) a combination of the olfactory receptor protein A and the olfactory receptor protein C, (2) a combination of the olfactory receptor protein A ' and the olfactory receptor protein B, and (3) the olfactory receptor protein B '.SELECTED DRAWING: None

The present invention discloses a D - psicose 3 - epimerase mutant and its application. Through the modification of the protein C - terminal sequence, software analysis, and sequence alignment of D - psicose 3 - epimerase from different sources, a D - psicose 3 - epimerase mutant is obtained, which enhances the half - life of the mutant enzyme at 60 °C, 70 °C, and 80 °C, improves the substrate affinity and conversion efficiency of the enzyme for the substrate D - fructose used in the synthesis of D - psicose. The Tm value of the mutant is 73.23 °C, which is 11.98 °C higher than that of the wild - type; the half - life at 60 °C is 255.35 min, which is 17.60 times that of the wild - type, improving the problem of the too short half - life of the wild - type at high temperature. The relative action time of the mutant enzyme is long. Using the genetically engineered bacterium containing the modified enzyme for biotransformation, the yield of the product D - psicose increases significantly, the product yield is increased by 4.3%, and the equilibrium conversion rate reaches 33%, providing a green, environmentally friendly, hygienic, and safe biological preparation method for the preparation process of D - psicose.

To provide a cancer inspection technique using an olfactory receptor.SOLUTION: A test agent for a cancer type a, comprising an insect olfactory receptor protein A having reactivity with the cancer type a and an insect olfactory receptor protein C having no reactivity with a cancer including the cancer type a.SELECTED DRAWING: None

The present invention belongs to the field of monoclonal antibody technology and relates to a monoclonal antibody targeting activated protein C (aPC). The amino acid sequences of the heavy and light chains of the monoclonal antibody are shown in SEQ ID NOs. 5 to 26, and the CDR sequences thereof are shown in SEQ ID NOs. 27 to 92. The present invention also provides biomaterials related to the monoclonal antibody, which selectively bind to aPC but not to inactivated protein C. The present invention also provides the use of the monoclonal antibody and related biomaterials in the preparation of drugs for treating coagulation deficiencies or defects, as well as related treatment methods, which have broad application prospects.

The present application relates to the technical field of molecular diagnosis and genotyping, and particularly relates to a VTE high-risk individual identification multiplex isothermal amplification detection method and a VTE high-risk individual identification multiplex isothermal amplification detection kit, a 4-7 SNP site detection panel containing SERPINC1 antithrombin deficiency variation, PROC protein C defect hotspot (p.Arg189Trp) and at least one SNP site in MTHFR, PAI-1, FGG and ABO is constructed; an allele-specific forward primer pair with a 3' end plus the second or third artificial mismatch double-mismatch anchoring structure, a universal reverse primer and a tetrahydrofuran site probe are designed for each SNP site; a risk stratification result is output by using an OR value weighted scoring model of a Chinese population cohort, the detection is rapid, single-tube multiplex, sample consumption is low, zero-instrument optional, and is suitable for rapid screening of genetic risk of venous thromboembolism in primary medical institutions of Chinese population.

To provide a method for screening an olfactory receptor protein or its combination useful in cancer examination.SOLUTION: A method for screening an olfactory receptor protein or a combination thereof, comprising testing the reactivity of a test olfactory receptor protein to cancer, and selecting at least one selected from the group consisting of (1) a combination of the olfactory receptor protein A and the olfactory receptor protein C, (2) a combination of the olfactory receptor protein A ' and the olfactory receptor protein B, and (3) the olfactory receptor protein B '.SELECTED DRAWING: None

The invention relates to a method for constructing a CDKL5 deficiency humanized mutation animal model and application of the CDKL5 deficiency humanized mutation animal model. The method comprises the step of knocking human CDKL5 gene R550X mutation and upstream and downstream genome sequences thereof into experimental animal genome CDKL5 gene loci. The human CDKL5 gene R550X mutation and upstream and downstream genome sequences thereof are knocked into experimental animal genome CDKL5 gene loci, CDKL5 protein C-terminal structural domain disease mutation is simulated, and the model has humanized mutation loci and nearby genome sequences, namely, has a to-be-repaired gene sequence same as that of a clinical patient, and can be applied to the field of clinical diagnosis and treatment of CDKL5 protein C-terminal structural domain disease mutation. The constructed model shows behavioral abnormality of a CDKL5 deficiency symptom, can be used for disease simulation and pathogenesis analysis of the CDKL5 deficiency symptom, can be used for directly testing gene editing and repairing strategies and therapeutic drugs of human genome specificity in the model body, and has important significance in the field of CDKL5 deficiency symptom treatment.

The present invention addresses the problem of providing a cancer testing feature using olfactory receptors. This problem is solved by a cancer type a testing agent comprising an insect olfactory receptor protein A having reactivity to cancer type a, and an insect olfactory receptor protein C having no reactivity to cancer including the cancer type a.

Disclosed are a trimerization regulatory element, a method for constructing same, and use thereof. In addition to a protein A and a protein B that are obtained by splitting the hepatitis C virus protease NS3a, the trimerization regulatory element comprises a protein C. The trimerization of the trimerization regulatory element can be mediated by means of a targeting drug specific to the protease NS3a (grazoprevir / danoprevir). The trimerization regulatory element provided by the present invention has an excellent small-molecule-mediated trimerization effect, and a drug approved by the National Medical Products Administration is used. The protein used does not exist in the human body; therefore, the protein can result in better biological orthogonality. Moreover, the protein can be used as a clinically effective drug regulatory switch, effectively avoiding problems such as serious cytotoxicity and off-target effects.

The invention provides an application of ZDHHC9 in preparation of a medicine for treating c-Myc abnormally activated tumors. According to the application, the fact that palmitoyl transferase ZDHHC9 can mediate cancer protein c-Myc to be subjected to palmitoyl modification so as to cause abnormal activation of the transcription function is proposed for the first time, and on the basis, after ZDHHC9 is down-regulated by utilizing an interfering RNA technology, the c-Myc transcription activity and malignant proliferation, clone formation and sphere formation capabilities of c-Myc abnormal activation type tumor cells are remarkably inhibited. The application disclosed by the invention not only discloses the effect of ZDHHC9 in c-Myc transcription function activation, but also provides a brand new therapeutic target for c-Myc abnormally activated tumors.

The invention provides a method of detecting or predicting a relapse of multiple sclerosis in an individual having a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample to determine a protein activity or protein level, wherein the protein is Factor VIII, von Willebrand Factor, or Protein C; and (c) detecting or predicting a relapse of multiple sclerosis in the individual if the protein activity or protein level is elevated compared to the protein activity or protein level in an individual not having the form of multiple sclerosis and the patient's own baseline value. The invention also provides a method of treating an individual having multiple sclerosis who is experiencing a relapse or is predicted to experience a relapse, comprising treating the individual by administering a dose of a steroid or an anticoagulant compound effective to reduce symptoms of multiple sclerosis.

The present application relates to protein C detection technical field, especially to protein C detection reagent, the kit can measure wide linear range, linear correlation coefficient is excellent, and also has higher sensitivity, stability and anti-interference ability, market competition advantage is big, can realize the substitution of import product, reduces the cost of clinical examination, satisfies the demand of clinical examination.

The invention provides application of tendon protein C in preparation of a medicine for promoting controllable regeneration or myocardial repair of myocardium. The invention also provides a heart patch which contains the tendon protein C. The invention also provides a preparation method of the heart patch. The invention also provides application of the heart patch in preparation of a medicine for preventing controllable regeneration or myocardial repair. By applying the method, the safety of myocardial regeneration can be improved, and the burden of the body caused by excessive increase of the heart is avoided.

The present disclosure relates to the production of oligosaccharides, especially Human milk Oligosaccharides (HMOs) using a genetically engineered cell which has decreased or total loss of function of phosphoglycerol transferase I and II and / or phosphoethanolamine transferase and / or glucans biosynthesis protein C to reduce oligosaccharide by-products and / or increase oligosaccharide production.

The invention relates to a specific small molecule compound of an FGL2 target spot and application thereof, and belongs to the field of biological medicine. Aiming at the problem that a specific inhibitor targeting an FGL2-Fc [gamma] RIIB signal channel is lacked in the prior art, the invention provides a small molecule compound with a molecular formula of C14H17N5O2. The compound blocks the combination of FGL2 and an Fc [gamma] RIIB receptor by being inserted into a pocket of a FGL2 protein C-terminal fibrinogen related domain (FRED), so that the depletion state of T cells is reversed. On one hand, the compound can be applied to the treatment of related diseases such as tumors with high expression of FGL2, and can also be applied to the clinical treatment of chronic virus infectious diseases such as HBV (Hepatitis B Virus) and HIV (Human Immunodeficiency Virus).

The invention discloses a gastric-soluble sustained-release tablet for preventing and treating helicobacter pylori infection and a preparation method of the gastric-soluble sustained-release tablet. The gastric-soluble sustained-release tablet comprises an active component and a sustained-release auxiliary material, the active component comprises a CagA protein targeting polypeptide, the CagA protein targeting polypeptide is a target HpCagA protein C terminal, and the amino acid sequence is shown as SEQ ID NO: 1. According to the sustained-release tablet, cell penetrating polypeptide targeting CagA protein is taken as an active ingredient, the effect is achieved by blocking CagA phosphorylation and downstream signal channels, meanwhile, the gastric-soluble sustained-release dosage form design is combined, the local high-concentration and long-acting effect is achieved, the dual effects of toxicity reduction and bacterium control are achieved, and the problems of drug resistance and side effects of antibiotics are solved.

This invention provides a protein composition that can enhance the proliferative activity of lentivirus-infected cells and its application. The protein composition includes at least one of protein A, protein B, and protein C; the amino acid sequence of protein A is selected from one of SEQ ID NO: 1-6; the amino acid sequence of protein B is selected from one of SEQ ID NO: 7-11; and the amino acid sequence of protein C is selected from one of SEQ ID NO: 12-13. By synthesizing a nucleic acid molecule encoding the protein composition provided by this invention, integrating it into a recombinant vector, and transfecting cells using a lentivirus transfection system, the lentivirus-infected cells can express the above-mentioned protein composition, thereby enhancing the proliferative activity of lentivirus-infected cells, reducing the risk of mass cell death after lentivirus infection, and allowing lentivirus-infected cells to survive well after a period of culture, thus improving the infection efficiency of lentivirus on cells.

The invention discloses snRNA for correcting protein C defects caused by exon-intron boundary mutation and application of the snRNA. Specific U1 small nuclear RNA (U1snRNA) and U7 small nuclear RNA (U7snRNA) are designed for protein C defects caused by abnormal mRNA splicing due to PROC gene exon-intron boundary mutation, so that recognition of 5'splicing sites is enhanced or recovered, and activated potential splicing sites are shielded. The small nuclear RNA is expressed through respective expression vectors, and corresponding U1snRNA or U7snRNA is correspondingly designed for each mutation. Cell experiment results show that the U1snRNA and the U7snRNA can remarkably recover correct splicing of abnormal PROC transcripts and improve the expression level and the functional activity of protein C. The invention provides a small nuclear RNA strategy based on RNA, which has potential gene therapy application value.

The invention relates to the technical field of protein C detection, in particular to a protein C detection reagent. The kit disclosed by the invention is wide in measurable linear range and excellent in linear correlation coefficient; meanwhile, the system also has relatively high sensitivity, stability and anti-interference capability; the market competitive advantage is great, the replacement of imported products can be realized, the cost of clinical examination is reduced, and the requirements of clinical examination are met.

The invention provides an African swine fever virus-like particle and application thereof in preparation of an African swine fever virus vaccine, and relates to the technical field of biology. The capsid protein, the protein A, the protein B and the protein C provided by the invention have good immune effects and can be used in African swine fever virus vaccines. Wherein the protein C is a four-layer nested particle and maintains a three-dimensional conformation of neutralizing epitopes on the surface of the particle, so that the structural rigidity of the particle is enhanced, and a better immune effect is achieved.

The present invention belongs to the field of enzyme engineering technology and discloses a highly active and stable PET hydrolase mutant and its application. The highly active and stable PET hydrolase mutant is Protein A, Protein B, or Protein C: Protein A is a wild-type cutinase TfCut in which amino acid position 132 is mutated from glutamine Q to lysine K; Protein B is a protein A modified by further mutating amino acids 244 and 293 to cysteine ​​C; and Protein C is a fusion protein containing Protein A or Protein B. The modified enzyme breaks the trade-off between catalytic activity and stability, significantly improving both its activity and thermal stability, thereby enhancing the industrial application value of PET hydrolase in PET degradation.

The present application belongs to the field of fish molecular immunology, and particularly relates to an oral vaccine containing a largemouth bass iridovirus ATPase and a preparation method thereof. B. subtilis The spores of the WB600 strain are antigen delivery carriers, the spore coat protein C (CotC) is used as an anchor protein, and the key protein of the largemouth bass iridovirus is fused with the ATPase gene and CotC the gene to construct a recombinant spore surface display system, so that the ATPase antigen is stably displayed on the spore surface, and an oral vaccine is prepared. The vaccine can tolerate the gastrointestinal environment after being orally administered to fish, and is accurately delivered to the gut-associated lymphoid tissue to stimulate the immunity of the fish, so that the prevention and control of the largemouth bass iridovirus is finally achieved.

Compositions and methods useful for the inhibition of cancer metastasis are disclosed.